These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 1466978)

  • 1. Highly attenuated poxvirus vectors.
    Tartaglia J; Cox WI; Taylor J; Perkus M; Riviere M; Meignier B; Paoletti E
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1445-7. PubMed ID: 1466978
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of lentivirus-like particles alone and in combination with live vaccinia-virus-based vaccines.
    Panicali DL; Mazzara G; Sullivan JL; Hesselton R; Shen L; Letvin N; Daniel M; Desrosiers R; Stott EJ
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1449. PubMed ID: 1466979
    [No Abstract]   [Full Text] [Related]  

  • 3. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein.
    Cox WI; Tartaglia J; Paoletti E
    Virology; 1993 Aug; 195(2):845-50. PubMed ID: 8337851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The poxvirus A35 protein is an immunoregulator.
    Rehm KE; Jones GJ; Tripp AA; Metcalf MW; Roper RL
    J Virol; 2010 Jan; 84(1):418-25. PubMed ID: 19828608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
    Paoletti E; Taylor J; Meignier B; Meric C; Tartaglia J
    Dev Biol Stand; 1995; 84():159-63. PubMed ID: 7796949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
    Didierlaurent A; Ramirez JC; Gherardi M; Zimmerli SC; Graf M; Orbea HA; Pantaleo G; Wagner R; Esteban M; Kraehenbuhl JP; Sirard JC
    Vaccine; 2004 Sep; 22(25-26):3395-403. PubMed ID: 15308364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes.
    Dai K; Liu Y; Liu M; Xu J; Huang W; Huang X; Liu L; Wan Y; Hao Y; Shao Y
    Vaccine; 2008 Sep; 26(39):5062-71. PubMed ID: 18573290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccinia and other poxvirus expression vectors.
    Moss B
    Curr Opin Biotechnol; 1992 Oct; 3(5):518-22. PubMed ID: 1368937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal poxvirus vaccines: a comprehensive review.
    Bhanuprakash V; Hosamani M; Venkatesan G; Balamurugan V; Yogisharadhya R; Singh RK
    Expert Rev Vaccines; 2012 Nov; 11(11):1355-74. PubMed ID: 23249235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
    Taylor J; Paoletti E
    Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poxviruses as vaccine vectors.
    Pastoret PP; Vanderplasschen A
    Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):343-55. PubMed ID: 12818621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.
    Ramírez JC; Gherardi MM; Rodríguez D; Esteban M
    J Virol; 2000 Aug; 74(16):7651-5. PubMed ID: 10906221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical development of Modified Vaccinia virus Ankara vaccines.
    Gilbert SC
    Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
    Moss B
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11341-8. PubMed ID: 8876137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poxvirus vector-based HIV vaccines.
    Pantaleo G; Esteban M; Jacobs B; Tartaglia J
    Curr Opin HIV AIDS; 2010 Sep; 5(5):391-6. PubMed ID: 20978379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poxvirus vectors: cytoplasmic expression of transferred genes.
    Moss B
    Curr Opin Genet Dev; 1993 Feb; 3(1):86-90. PubMed ID: 8453278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.
    Price PJ; Torres-Domínguez LE; Brandmüller C; Sutter G; Lehmann MH
    Vaccine; 2013 Sep; 31(39):4231-4. PubMed ID: 23523404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.